文献速递哮喘

肥胖相关哮喘:基于病理生物学的现有与新兴治疗综述

Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

本文综述肥胖相关哮喘现有及新兴治疗方法的证据,指出二甲双胍和GLP-1受体激动剂与哮喘结局改善相关,但GLP-1R激动剂数据限于合并肥胖者;生物制剂在肥胖者中一般有效但证据来自回顾性或二次分析;IL-6、精氨酸代谢物、硝基脂肪酸等靶点正在临床试验中。

要点

  • 二甲双胍和GLP-1受体激动剂与肥胖相关哮喘结局改善相关,但GLP-1R数据限于合并肥胖者。
  • 获批生物制剂在肥胖者中一般有效,证据来自回顾性或临床试验二次分析,青少年影响未充分研究。
  • IL-6、精氨酸代谢物、硝基脂肪酸、线粒体抗氧化剂等靶点临床试验正在进行。

核心结论

  • 肥胖相关哮喘治疗选择仍有限,需进一步研究其独特炎症通路以开发有效疗法。

研究设计与样本

  • 本文为最先进综述,综合现有及新兴治疗方法的证据,并指出潜在新药靶点通路。

主要发现

  • 二甲双胍和GLP-1受体激动剂与哮喘结局改善相关,但GLP-1R激动剂数据限于合并肥胖者。
  • 获批用于中重度哮喘的单克隆抗体在肥胖者中一般有效,证据来自回顾性或临床试验二次分析。
  • 多数哮喘生物制剂获批用于儿科人群,但肥胖对其疗效的影响在青少年中未充分研究。
  • 正在研究的潜在靶点包括IL-6、精氨酸代谢物、硝基脂肪酸和线粒体抗氧化剂,均有临床试验在进行。
  • 潜在靶点还包括脂肪组织嗜酸性粒细胞和GLP-1-精氨酸-晚期糖基化终产物轴,但尚需人体数据。

临床怎么用

  • 对肥胖相关哮喘患者,可考虑二甲双胍或GLP-1受体激动剂以改善哮喘结局,尤其合并肥胖者。
  • 获批生物制剂在肥胖者中一般仍有效,但青少年肥胖对疗效影响未充分研究。

局限性

  • GLP-1R激动剂在哮喘中的数据限于合并肥胖个体。
  • 生物制剂在肥胖者中的疗效证据基于回顾性或临床试验二次分析。
  • 肥胖对哮喘生物制剂在青少年中疗效的影响未充分研究。
  • 脂肪组织嗜酸性粒细胞和GLP-1-精氨酸-AGE轴等靶点尚需人体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although obesity-related asthma is associated with worse asthma outcomes, optimal treatment approaches for this complex phenotype are still largely unavailable. This state-of-the-art review article synthesizes evidence for existing and emerging treatment approaches for obesity-related asthma and highlights pathways that offer potential targets for novel therapeutics. Existing treatments targeting insulin resistance and obesity, including metformin and GLP-1 (glucagon-like-peptide 1) receptor agonists, have been associated with improved asthma outcomes, although GLP-1R agonist data in asthma are limited to individuals with comorbid obesity. Monoclonal antibodies approved for treatment of moderate to severe asthma generally appear to be effective in individuals with obesity, although this is based on retrospective or secondary analysis of clinical trials; moreover, although most of these asthma biologics are approved for use in the pediatric population, the impact of obesity on their efficacy has not been well studied in youth. Potential therapeutic targets being investigated include IL-6, arginine metabolites, nitro-fatty acids, and mitochondrial antioxidants, with clinical trials for each currently underway. Potential therapeutic targets include adipose tissue eosinophils and the GLP-1-arginine-advanced glycation end products axis, although data in humans are still needed. Finally, transcriptomic and epigenetic studies of "obese asthma" demonstrate enrichment of IFN-related signaling pathways, Rho-GTPase pathways, and integrins, suggesting that these too could represent future treatment targets. We advocate for further study of these potential therapeutic mechanisms and continued investigation of the distinct inflammatory pathways characteristic of obesity-related asthma, to facilitate effective treatment development for this unique asthma phenotype.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Althoff MD, Gaietto K, Holguin F, et al. Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches. Am J Respir Crit Care Med. 2024. PMID: 39311907. doi:10.1164/rccm.202406-1166SO

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。